JP2022081492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022081492A5 JP2022081492A5 JP2022021751A JP2022021751A JP2022081492A5 JP 2022081492 A5 JP2022081492 A5 JP 2022081492A5 JP 2022021751 A JP2022021751 A JP 2022021751A JP 2022021751 A JP2022021751 A JP 2022021751A JP 2022081492 A5 JP2022081492 A5 JP 2022081492A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- vaccine
- protein
- fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024045130A JP2024096712A (ja) | 2016-05-13 | 2024-03-21 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
| JP2024103724A JP2024160216A (ja) | 2016-05-13 | 2024-06-27 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/060897 WO2017194170A1 (en) | 2016-05-13 | 2016-05-13 | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| EPPCT/EP2016/060897 | 2016-05-13 | ||
| PCT/EP2017/061196 WO2017194610A1 (en) | 2016-05-13 | 2017-05-10 | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| JP2018559794A JP7529381B2 (ja) | 2016-05-13 | 2017-05-10 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559794A Division JP7529381B2 (ja) | 2016-05-13 | 2017-05-10 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045130A Division JP2024096712A (ja) | 2016-05-13 | 2024-03-21 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022081492A JP2022081492A (ja) | 2022-05-31 |
| JP2022081492A5 true JP2022081492A5 (https=) | 2022-12-16 |
Family
ID=55971007
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559794A Active JP7529381B2 (ja) | 2016-05-13 | 2017-05-10 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
| JP2022021751A Pending JP2022081492A (ja) | 2016-05-13 | 2022-02-16 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
| JP2024045130A Pending JP2024096712A (ja) | 2016-05-13 | 2024-03-21 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
| JP2024069742A Pending JP2024112805A (ja) | 2016-05-13 | 2024-04-23 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
| JP2024103724A Pending JP2024160216A (ja) | 2016-05-13 | 2024-06-27 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559794A Active JP7529381B2 (ja) | 2016-05-13 | 2017-05-10 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045130A Pending JP2024096712A (ja) | 2016-05-13 | 2024-03-21 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
| JP2024069742A Pending JP2024112805A (ja) | 2016-05-13 | 2024-04-23 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
| JP2024103724A Pending JP2024160216A (ja) | 2016-05-13 | 2024-06-27 | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12153041B2 (https=) |
| EP (3) | EP4411376A3 (https=) |
| JP (5) | JP7529381B2 (https=) |
| KR (3) | KR20220020993A (https=) |
| CN (1) | CN109073637A (https=) |
| AU (2) | AU2017264546B2 (https=) |
| BR (1) | BR112018073221A2 (https=) |
| CA (1) | CA3022654A1 (https=) |
| CY (1) | CY1123520T1 (https=) |
| DK (2) | DK3792628T3 (https=) |
| ES (2) | ES2826480T3 (https=) |
| FI (1) | FI3792628T3 (https=) |
| HR (2) | HRP20240704T1 (https=) |
| HU (2) | HUE067497T2 (https=) |
| IL (2) | IL300841A (https=) |
| LT (2) | LT3455625T (https=) |
| MA (1) | MA43794B1 (https=) |
| MD (1) | MD3455625T2 (https=) |
| MX (2) | MX393653B (https=) |
| PL (2) | PL3455625T3 (https=) |
| PT (2) | PT3792628T (https=) |
| RS (2) | RS65568B1 (https=) |
| SG (1) | SG11201808495SA (https=) |
| SI (2) | SI3792628T1 (https=) |
| SM (2) | SMT202400232T1 (https=) |
| WO (2) | WO2017194170A1 (https=) |
| ZA (1) | ZA201805809B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL260030B2 (en) | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| WO2017194170A1 (en) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| EP3933408A1 (en) | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
| JP6857930B2 (ja) * | 2018-02-15 | 2021-04-14 | 国立大学法人旭川医科大学 | がん抗原ペプチド |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US20220349010A1 (en) | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| CN109021062B (zh) * | 2018-08-06 | 2021-08-20 | 倍而达药业（苏州）有限公司 | 一种肿瘤新抗原的筛选方法 |
| CN111621564B (zh) * | 2019-02-28 | 2022-03-25 | 武汉大学 | 一种鉴定有效肿瘤新抗原的方法 |
| TWI894138B (zh) * | 2019-03-06 | 2025-08-21 | 美商西雅圖項目公司 | 利用ii 類mhc 模型鑑別新抗原 |
| CN110534156B (zh) * | 2019-09-02 | 2022-06-17 | 深圳市新合生物医疗科技有限公司 | 一种提取免疫治疗新抗原的方法及系统 |
| CN111487399B (zh) * | 2020-03-26 | 2021-09-17 | 湖南师范大学 | 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用 |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766205B1 (fr) * | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| DK1276896T3 (da) * | 2000-04-28 | 2010-10-18 | Mannkind Corp | Epitop-synkronisering i antigen-præsenterende celler |
| CA2415902A1 (en) | 2000-07-10 | 2002-01-17 | Xencor | Protein design automation for designing protein libraries with altered immunogenicity |
| JP4900884B2 (ja) * | 2000-07-31 | 2012-03-21 | 株式会社グリーンペプタイド | 腫瘍抗原 |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
| WO2006105255A2 (en) * | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Cancer vaccines and therapeutic methods |
| JP2009273377A (ja) * | 2008-05-12 | 2009-11-26 | Igaku Seibutsugaku Kenkyusho:Kk | Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法 |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| CA2755983A1 (en) | 2009-03-23 | 2010-09-30 | The Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for modulating an immune response |
| AU2010310468A1 (en) * | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| EP2714730A1 (en) * | 2011-06-01 | 2014-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel antigen peptide and uses thereof |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| WO2017194170A1 (en) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| CA3060569A1 (en) | 2017-04-19 | 2018-10-25 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| AU2018279627B2 (en) | 2017-06-09 | 2023-08-10 | Seattle Project Corp. | Neoantigen identification, manufacture, and use |
| US20200363414A1 (en) | 2017-09-05 | 2020-11-19 | Gritstone Oncology, Inc. | Neoantigen Identification for T-Cell Therapy |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| EP3759131A4 (en) | 2018-02-27 | 2021-12-01 | Gritstone bio, Inc. | NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS |
-
2016
- 2016-05-13 WO PCT/EP2016/060897 patent/WO2017194170A1/en not_active Ceased
-
2017
- 2017-05-10 EP EP24171718.0A patent/EP4411376A3/en active Pending
- 2017-05-10 HU HUE20193183A patent/HUE067497T2/hu unknown
- 2017-05-10 MA MA43794A patent/MA43794B1/fr unknown
- 2017-05-10 MD MDE20190332T patent/MD3455625T2/ro unknown
- 2017-05-10 PT PT201931839T patent/PT3792628T/pt unknown
- 2017-05-10 MX MX2018013081A patent/MX393653B/es unknown
- 2017-05-10 BR BR112018073221-4A patent/BR112018073221A2/pt unknown
- 2017-05-10 JP JP2018559794A patent/JP7529381B2/ja active Active
- 2017-05-10 WO PCT/EP2017/061196 patent/WO2017194610A1/en not_active Ceased
- 2017-05-10 HU HUE17726208A patent/HUE052240T2/hu unknown
- 2017-05-10 LT LTEP17726208.6T patent/LT3455625T/lt unknown
- 2017-05-10 HR HRP20240704TT patent/HRP20240704T1/hr unknown
- 2017-05-10 FI FIEP20193183.9T patent/FI3792628T3/fi active
- 2017-05-10 ES ES17726208T patent/ES2826480T3/es active Active
- 2017-05-10 KR KR1020227002915A patent/KR20220020993A/ko not_active Ceased
- 2017-05-10 EP EP17726208.6A patent/EP3455625B1/en active Active
- 2017-05-10 AU AU2017264546A patent/AU2017264546B2/en active Active
- 2017-05-10 SG SG11201808495SA patent/SG11201808495SA/en unknown
- 2017-05-10 RS RS20240614A patent/RS65568B1/sr unknown
- 2017-05-10 US US16/301,019 patent/US12153041B2/en active Active
- 2017-05-10 PT PT177262086T patent/PT3455625T/pt unknown
- 2017-05-10 CN CN201780026579.0A patent/CN109073637A/zh active Pending
- 2017-05-10 DK DK20193183.9T patent/DK3792628T3/da active
- 2017-05-10 HR HRP20201671TT patent/HRP20201671T1/hr unknown
- 2017-05-10 SM SM20240232T patent/SMT202400232T1/it unknown
- 2017-05-10 IL IL300841A patent/IL300841A/en unknown
- 2017-05-10 PL PL17726208T patent/PL3455625T3/pl unknown
- 2017-05-10 KR KR1020187032652A patent/KR102358620B1/ko active Active
- 2017-05-10 RS RS20201233A patent/RS61071B1/sr unknown
- 2017-05-10 DK DK17726208.6T patent/DK3455625T3/da active
- 2017-05-10 ES ES20193183T patent/ES2980781T3/es active Active
- 2017-05-10 PL PL20193183.9T patent/PL3792628T3/pl unknown
- 2017-05-10 SI SI201731526T patent/SI3792628T1/sl unknown
- 2017-05-10 EP EP20193183.9A patent/EP3792628B1/en active Active
- 2017-05-10 LT LTEP20193183.9T patent/LT3792628T/lt unknown
- 2017-05-10 SI SI201730466T patent/SI3455625T1/sl unknown
- 2017-05-10 CA CA3022654A patent/CA3022654A1/en active Pending
- 2017-05-10 KR KR1020247031632A patent/KR20240146087A/ko active Pending
- 2017-05-10 SM SM20200622T patent/SMT202000622T1/it unknown
-
2018
- 2018-08-29 ZA ZA2018/05809A patent/ZA201805809B/en unknown
- 2018-10-25 MX MX2022007902A patent/MX2022007902A/es unknown
- 2018-10-29 IL IL262680A patent/IL262680B2/en unknown
-
2020
- 2020-10-14 CY CY20201100969T patent/CY1123520T1/el unknown
-
2022
- 2022-02-16 JP JP2022021751A patent/JP2022081492A/ja active Pending
- 2022-07-27 AU AU2022209286A patent/AU2022209286A1/en active Pending
-
2024
- 2024-03-21 JP JP2024045130A patent/JP2024096712A/ja active Pending
- 2024-04-23 JP JP2024069742A patent/JP2024112805A/ja active Pending
- 2024-06-27 JP JP2024103724A patent/JP2024160216A/ja active Pending
- 2024-10-18 US US18/920,525 patent/US20250244311A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022081492A5 (https=) | ||
| Kawakami et al. | Human tumor antigens recognized by T-cells | |
| JP2021517810A5 (https=) | ||
| Kawashima et al. | Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells | |
| JP2021036867A5 (https=) | ||
| JP2019520591A5 (https=) | ||
| IL300841A (en) | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy | |
| CN109021062A (zh) | 一种肿瘤新抗原的筛选方法 | |
| Willimsky et al. | In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo | |
| Aguilar-Gurrieri et al. | Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines | |
| US9720000B2 (en) | Targeted identification of immunogenic peptides | |
| CN109234283B (zh) | 肿瘤相关基因cdh1突变短肽及其应用 | |
| Lown et al. | Magnetic bead-immobilized mammalian cells are effective targets to enrich ligand-displaying yeast | |
| CN107987164A (zh) | 雌激素受体ER-α36抗原多肽及其单克隆抗体 | |
| Apostolopoulos et al. | The immunogenicity of MUC1 peptides and fusion protein | |
| CN109758590B (zh) | 一种用于筛选人前列腺癌肿瘤抗原表位肽的方法 | |
| Durrant et al. | Production of monoclonal antibodies recognising the peptide core of MUC2 intestinal mucin | |
| Hashemzadeh et al. | Novel predicted B-cell epitopes of PSMA for development of prostate cancer vaccine | |
| CN103728456A (zh) | 胸腺嘧啶核苷激酶的elisa诊断试剂盒 | |
| CN102973950B (zh) | Prame、wt1双价肿瘤dna疫苗 | |
| Zahraei et al. | In silico design of a multi-epitope vaccine against the triple negative breast cancer | |
| JP2012072167A (ja) | 免疫源性ペプチドの標的特異的同定方法 | |
| Xing et al. | Peptide epitopes in breast cancer mucins | |
| Dunphy et al. | New approaches to identification of antigenic candidates for future prostate cancer immunotherapy | |
| Brown et al. | Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes |